p23780377-8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2011
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
| |
|
14 Plaza Drive, Latham, New York 12110
|
|
(Address of Principal Executive Offices) (Zip Code)
|
| |
|
(518) 798-1215
|
|
(Registrant’s telephone number, including area code)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 3, 2011, the Board of Directors of AngioDynamics, Inc. (the “Company”) approved additional compensation for Scott J. Solano, the Company’s Interim CEO, in recognition of Mr. Solano’s services as Interim CEO. For such services, Mr. Solano will receive a lump sum cash payment of $31,233 and a grant of 4,617 shares of immediately vested restricted common stock of the Company at a value of $13.53 per share, the closing price of the Company’s common stock as reported on the NASDAQ Global Market on the date of the grant.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ANGIODYNAMICS, INC.
(Registrant)
|
|
| |
|
|
|
|
Date: August 5, 2011
|
By:
|
/s/ D. Joseph Gersuk |
|
| |
|
D. Joseph Gersuk |
|
| |
|
Chief Financial Officer |
|
| |
|
|
|